Curcumin Augments Gemcitabine Cytotoxic Effect on Pancreatic Adenocarcinoma Cell Lines
- 1 January 2007
- journal article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 25 (6) , 411-418
- https://doi.org/10.1080/07357900701359577
Abstract
Gemcitabine, the first-line agent in pancreatic adenocarcinoma, has shown limited clinical benefit. Cyclooxygenase-2 (COX-2) represent one of the most promising targets for cancer prevention and treatment. In this study, we investigated whether the phytochemical curcumin, a natural COX-2 inhibitor, can potentiate gemcitabine effect on survival of human pancreatic cancer cells. P34 (high COX-2 expression) and Panc-1 (low COX-2 expression) pancreatic cancer cell lines were exposed to different concentrations of gemcitabine (0.1-10 microM), curcumin (0-50 microM), and their combination. Cell viability was evaluated by XTT assay. Cell cycle and apoptosis were assessed by flow cytometry. COX-2, EGFR, and p-ERK1/2 expression was measured by Western blot analysis. Curcumin increased the inhibitory effect of gemcitabine on cell viability as well as its pro-apoptotic effect in COX-2 positive, p34 cells, but not in COX-2 negative, Panc-1 cells. In p34 cells, combination of curcumin and gemcitabine downregulated both COX-2 and p-ERK1/2 in a dose-dependent manner. The increased cytotoxic effect of the combination on cell survival and on the induction of apoptosis in COX-2 expressing pancreatic cancer cells is probably associated with downregulation of COX-2 and p-ERK1/2 levels. This finding may contribute to the development of an effective treatment of pancreatic adenocarcinoma.Keywords
This publication has 40 references indexed in Scilit:
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Phase I Clinical Trial of Oral CurcuminClinical Cancer Research, 2004
- Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administrationBritish Journal of Cancer, 2004
- Prostaglandins and Leukotrienes: Advances in Eicosanoid BiologyScience, 2001
- Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2Nature Reviews Cancer, 2001
- Prostaglandin E2 Increases Growth and Motility of Colorectal Carcinoma CellsJournal of Biological Chemistry, 2001
- The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritisArthritis & Rheumatism, 2000
- Indomethacin-Induced Apoptosis in Esophageal Adenocarcinoma Cells Involves Upregulation of Bax and Translocation of Mitochondrial Cytochrome C Independent of COX-2 ExpressionNeoplasia, 2000